DB17243InvestigationalProtein Based Therapies
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with...
- Mechanism
- Curator reviewed
Pharmacologically active on T-lymphocyte activation antigen CD80 and Interleukin-2
- Code names
- GI-101 · SIM0323 · SIM-323
Resolves to
Compound
Targets
What you can answer from here — as of October 20, 2026
Which drugs share a target with GI-101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account